Skip to main content
Caplight Logo









Kanyr Pharma

Kanyr Pharma

Private
MontrealHealthcare & Life Scienceshttps://kanyrpharma.com/

Last Round

Grant

Jun 5, 2023

Total Funding Raised

$680,000

Company Overview

Kanyr Pharma is a biotechnology company that develops innovative protein tyrosine phosphatase (PTP) inhibitor-based therapies for the treatment of cancer and other human diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryprotein tyrosine phosphatasePTP inhibitorsimmunotherapysmall molecule inhibitorsoncologyundruggable targetspreclinical researchbiotech startupdrug pipelinetherapeutic developmentpharma licensingsolid tumor therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kanyr Pharma Comparables

Compare Kanyr Pharma with similar companies based on industry and business-model similarity.

Kanyr Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DepYmed, Inc.
84%
BridgeBio Pharma, Inc.
76%
Jacobio Pharmaceuticals Group Co Ltd
72%

Kanyr Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 5, 2023
GrantJun 17, 2020

Kanyr Pharma Investors

Notable investors and investment history

Kanyr Pharma Filings

Explore SEC and related filing metadata, where available.

Kanyr Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kanyr Pharma's valuation, stock price, and market status.

Is Kanyr Pharma a public or private company?

Kanyr Pharma is a private company.

What is the current stock price of Kanyr Pharma?

Kanyr Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Kanyr Pharma worth (valuation)?

Valuation information for Kanyr Pharma is not publicly available.

Can I buy Kanyr Pharma stock?

Kanyr Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kanyr Pharma's last funding round?

Kanyr Pharma's most recent funding round was Grant on June 5, 2023.

Who are the main investors in Kanyr Pharma?

Key investors in Kanyr Pharma include Consortium Québécois sur la découverte du médicament.

Will Kanyr Pharma IPO soon?

No public IPO plans have been announced for Kanyr Pharma.

How can I track Kanyr Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kanyr Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontreal
Employee Range1
Year Founded2013
Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?